Antithrombin III deficiency
was detected in 9/404 (2%) patients and FVL in 25/173 patients (14.
The etiology of thrombus formation in a macroscopically normal aorta is not well understood and has been attributed to various hypercoagulable disorders, including combined protein C and protein S deficiency, (17,10,11) elevated levels of clotting factor VIII, antithrombin III deficiency
, (7) polycythemia vera, (7) essential thrombocythemia, (12) hyperhomocysteinaemia, (13) increased fibrinogen, (4) as well as autoimmune diseases with hypercoagulable states, e.
When GTC won regulatory approval to sell ATryn in 2009, it was after a hearing in which New Mexico lawyer Karen Janes spoke about her hope for a treatment that could help her daughter, who inherited an antithrombin III deficiency
Differential diagnosis of DIC included microangiopathic pathologies like infectious reasons (purpura fulminans), soft tissue injury due to trauma, snake or insect venom, severe thrombotic, thrombocytopenic purpura and hemolytic uremic syndrome and hereditary thrombotic abnormalities like antithrombin III deficiency
, and heterozygous PC and PS deficiency.
The new product, which is a human antithrombin III concentrate, is indicated for the treatment of thrombosis associated with congenital antithrombin III deficiency
as well as disseminated intravascular coagulation.
It's important to routinely search for these abnormalities as well as for the other leading inherited thrombophilias--factor V Leiden mutation, prothrombin gene mutations, antithrombin III deficiency
, protein S deficiency and protein C deficiency--in all women with a history of venous thromboembolism who are pregnant or planning pregnancy.
An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency
than an assay based on thrombin inhibition.
Primary hypercoagulable states involve specific abnormalities of hemostasis and include antithrombin III deficiency
, protein C deficiency, protein S deficiency, lupus anticoagulant, disorders of fibrinolytic system (eg, disorders of tissue plasminogen activator, abnormal plasminogen and hypoplasminogenemia), dysfibrinogenemia factor XII deficiency, and anticardiolipin antibody syndrome.
The claims of this new patent relate to a method of treating subjects having an antithrombin III deficiency
or inflammation with the administration of recombinant antithrombin III produced in the mammary gland of a non-human mammal.
This agent is indicated for patients with hereditary antithrombin III deficiency
or thromboembolism and is rated pregnancy risk category B.
7%) exhibited protein S deficiency, whereas no patient had antithrombin III deficiency
These causes include polycythemia, thrombocytosis, antithrombin III deficiency
, and protein C or protein S deficiency.